Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

A breast multi-disciplinary genomic tumor board is feasible and can provide timely and impactful recommendations.

Tsung K, Thompson CL, Knight JM, Maximuk S, Sadri N, Gilmore H, Keri RA, Vinayak S, Harris L, Silverman P.

Breast J. 2018 Jul;24(4):676-677. doi: 10.1111/tbj.13027. Epub 2018 Mar 8. No abstract available.

PMID:
29517142
2.

Neoadjuvant systemic therapy in invasive lobular breast cancer: Is it indicated?

Tsung K, Grobmyer SR, Tu C, Abraham J, Budd GT, Valente SA.

Am J Surg. 2018 Mar;215(3):509-512. doi: 10.1016/j.amjsurg.2017.11.011. Epub 2017 Nov 14.

PMID:
29197477
3.

Tumor reductive therapies and antitumor immunity.

Guo H, Tsung K.

Oncotarget. 2017 Jun 14;8(33):55736-55749. doi: 10.18632/oncotarget.18469. eCollection 2017 Aug 15. Review.

4.

Copulatory plugs inhibit the reproductive success of rival males.

Mangels R, Tsung K, Kwan K, Dean MD.

J Evol Biol. 2016 Nov;29(11):2289-2296. doi: 10.1111/jeb.12956. Epub 2016 Aug 23.

5.

In situ vaccine, immunological memory and cancer cure.

Tsung K, Norton JA.

Hum Vaccin Immunother. 2016;12(1):117-9. doi: 10.1080/21645515.2015.1073427. Epub 2015 Sep 11.

6.

An immunological view of chemotherapy.

Tsung K, Norton JA.

Immunotherapy. 2015;7(9):941-3. doi: 10.2217/imt.15.62. Epub 2015 Aug 27. No abstract available.

7.

Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer.

Chien AJ, Duralde E, Hwang R, Tsung K, Kao CN, Rugo HS, Melisko ME, Esserman LJ, Munster PN, Cedars M, Kerlikowske K, McCulloch CE, Rosen MP.

Breast Cancer Res Treat. 2015 Aug;153(1):173-81. doi: 10.1007/s10549-015-3511-3. Epub 2015 Jul 25.

PMID:
26208485
8.

IL-12 augments antitumor responses to cycled chemotherapy.

Zhang L, Feng D, Hu Y, Tsung K, Norton JA.

J Immunother. 2015 May;38(4):137-44. doi: 10.1097/CJI.0000000000000074.

PMID:
25839439
9.

Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25.

Fejerman L, Ahmadiyeh N, Hu D, Huntsman S, Beckman KB, Caswell JL, Tsung K, John EM, Torres-Mejia G, Carvajal-Carmona L, Echeverry MM, Tuazon AM, Ramirez C; COLUMBUS Consortium, Gignoux CR, Eng C, Gonzalez-Burchard E, Henderson B, Le Marchand L, Kooperberg C, Hou L, Agalliu I, Kraft P, Lindström S, Perez-Stable EJ, Haiman CA, Ziv E.

Nat Commun. 2014 Oct 20;5:5260. doi: 10.1038/ncomms6260.

10.

Polarized deposition of basement membrane proteins depends on Phosphatidylinositol synthase and the levels of Phosphatidylinositol 4,5-bisphosphate.

Devergne O, Tsung K, Barcelo G, Schüpbach T.

Proc Natl Acad Sci U S A. 2014 May 27;111(21):7689-94. doi: 10.1073/pnas.1407351111. Epub 2014 May 14.

11.

Neuropeptide orphanin FQ inhibits dendritic morphogenesis through activation of RhoA.

Alder J, Kallman S, Palmieri A, Khadim F, Ayer JJ, Kumar S, Tsung K, Grinberg I, Thakker-Varia S.

Dev Neurobiol. 2013 Oct;73(10):769-84. doi: 10.1002/dneu.22101. Epub 2013 Aug 20.

12.

Preexisting antitumor immunity augments the antitumor effects of chemotherapy.

Zhang L, Feng D, Yu LX, Tsung K, Norton JA.

Cancer Immunol Immunother. 2013 Jun;62(6):1061-71. doi: 10.1007/s00262-013-1417-7. Epub 2013 Apr 18.

PMID:
23595208
13.

Lessons from Coley's Toxin.

Tsung K, Norton JA.

Surg Oncol. 2006 Jul;15(1):25-8. Epub 2006 Jun 30. Review.

PMID:
16814541
14.
15.

Antitumor immunity induced by dendritic cell-based vaccination is dependent on interferon-gamma and interleukin-12.

Hiramoto JS, Tsung K, Bedolli M, Norton JA, Hirose R.

J Surg Res. 2004 Jan;116(1):64-9.

PMID:
14732350
16.

Cure of an established nonimmunogenic tumor, SCC VII, with a novel interleukin 12-based immunotherapy regimen in C3H mice.

Mandpe AH, Tsung K, Norton JA.

Arch Otolaryngol Head Neck Surg. 2003 Jul;129(7):786-92.

PMID:
12874083
17.
18.

Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection.

Tsung K, Dolan JP, Tsung YL, Norton JA.

Cancer Res. 2002 Sep 1;62(17):5069-75.

19.

The role of IFN-gamma in rejection of established tumors by IL-12 : source of production and target.

Segal JG, Lee NC, Tsung YL, Norton JA, Tsung K.

Cancer Res. 2002 Aug 15;62(16):4696-703.

20.
21.

Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen.

Carroll MW, Overwijk WW, Surman DR, Tsung K, Moss B, Restifo NP.

J Natl Cancer Inst. 1998 Dec 16;90(24):1881-7.

22.

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.

Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP.

J Exp Med. 1998 Jul 20;188(2):277-86.

23.

Vaccinia virus for human gene therapy.

Peplinski GR, Tsung K, Norton JA.

Surg Oncol Clin N Am. 1998 Jul;7(3):575-88. Review.

PMID:
9624218
24.

Immune response against large tumors eradicated by treatment with cyclophosphamide and IL-12.

Tsung K, Meko JB, Tsung YL, Peplinski GR, Norton JA.

J Immunol. 1998 Feb 1;160(3):1369-77.

26.
27.

IL-12 induces T helper 1-directed antitumor response.

Tsung K, Meko JB, Peplinski GR, Tsung YL, Norton JA.

J Immunol. 1997 Apr 1;158(7):3359-65.

PMID:
9120294
28.
29.
30.
31.
32.

Endogenous interferon-gamma acts directly on tumor cells in vivo to suppress growth.

Doherty GM, Tsung K, McCluskey B, Norton JA.

J Surg Res. 1996 Jul 15;64(1):68-74.

PMID:
8806476
33.

Prevention of murine breast cancer by vaccination with tumor cells modified by cytokine-producing recombinant vaccinia viruses.

Peplinski GR, Tsung K, Meko JB, Norton JA.

Ann Surg Oncol. 1996 Jan;3(1):15-23. Erratum in: Ann Surg Oncol 1996 Mar;3(2):231.

PMID:
8770297
34.

Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light.

Tsung K, Yim JH, Marti W, Buller RM, Norton JA.

J Virol. 1996 Jan;70(1):165-71.

35.
36.

In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1 beta.

Peplinski GR, Tsung K, Meko JB, Norton JA.

Surgery. 1995 Aug;118(2):185-90; discussion 190-1.

PMID:
7638732
37.

An unusual cause of dysphagia.

Tsung K, Seggev JS.

West J Med. 1995 Aug;163(2):159-60. No abstract available.

38.

IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases.

Bronte V, Tsung K, Rao JB, Chen PW, Wang M, Rosenberg SA, Restifo NP.

J Immunol. 1995 May 15;154(10):5282-92.

39.

Prolongation of skin allografts by recombinant tumor necrosis factor and interleukin-1.

Parenteau GL, Doherty GM, Peplinski GR, Tsung K, Norton JA.

Ann Surg. 1995 May;221(5):572-7; discussion 577-8.

40.

Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta.

Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA.

Ann Surg Oncol. 1995 Mar;2(2):151-9.

PMID:
7728569
41.

In vitro and in vivo kinetics of recombinant vaccinia virus cancer-gene therapy.

Whitman ED, Tsung K, Paxson J, Norton JA.

Surgery. 1994 Aug;116(2):183-8.

PMID:
8047984
42.
45.
49.
50.

Regulation of the ompC gene of Escherichia coli. Involvement of three tandem promoters.

Ikenaka K, Ramakrishnan G, Inouye M, Tsung K, Inouye M.

J Biol Chem. 1986 Jul 15;261(20):9316-20.

Supplemental Content

Support Center